Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eric Simpson
Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD
Tilrekimig (PF-07275315), an investigational trispecific antibody against interleukin (IL)-4, IL-13, and thymic stromal lymphopoietin (TSLP), achieved EASI-75 in up to 63% of biologic-naive adults with moderate to severe atopic dermatitis at week 16 in phase 2 data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna.¹,2 The molecule pairs the IL-4/IL-13 pathway blockade of dupilumab (Dupixent) with inhibition of TSLP, an upstream target already...
Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation
Abstract Atopic diseases arise from an immunological imbalance where regulatory mechanisms are unable to preserve or restore homeostasis, leading to chronic inflammatory conditions affecting epithelial organs. This may involve homeostasis, deficient or insufficient regulatory T cells (Tregs) or other aberrant regulatory mechanisms.
Emollients to Prevent Pediatric Eczema:: a Randomized Clinical Trial
Ayuda Buscar en la ayuda Buscar en la ayuda Emollients to Prevent Pediatric Eczema:: a Randomized Clinical Trial L. Simpson, Eric [2] ; Michaels, Leann C. [3] ; Katrina, Ramsey [1] [1] Musgrove Park Hospital Taunton Deane District, Reino Unido [2] MD, MCR [3] BS Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 161, Nº. 9, 2025, págs.
Emollients to Prevent Pediatric Eczema
Supplement 1. Supplement 2. Statistical analysis plan Supplement 3. eTable 1. Characteristics of participating clinics eTable 2. Baseline emollients received, intervention arm only eFigure 1. Emollient changes during study participation (intervention arm n=603) eTable 3. Detailed data of adherence eFigure 2. Risk differences by emollient shipped at enrollment compared to none eFigure 3.
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
Ayuda Buscar en la ayuda Buscar en la ayuda Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials Autores: Eric L. Simpson, Lawrence F. Eichenfield, Javier Alonso Llamazares, Zoe Diana Draelos, Laura K. Ferris, Seth B. Forman, Melinda J. Gooderham, Mercedes E. Gonzalez, Adelaide A. Hebert, Leon H. Kircik, Mark Lomaga, Angela Moore, Kim A. Papp, Vimal H.
Roflumilast cream 0.15% addresses unmet needs of adults, children with atopic dermatitis
You've successfully added Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: More patients treated with roflumilast vs. vehicle achieved a validated IGA-AD score of 0/1. More than 95% of roflumilast-treated patients reported no signs of application site irritation.
Orismilast demonstrates efficacy, early itch reduction in atopic dermatitis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Orismilast 40 mg group achieved the best results with 31% of patients reaching IGA 0 or 1 by week 16. IGA 0 or 1 was also achieved by 26% and 30 mg of the orismilast 20 mg and 30 mg groups, respectively.
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children
Key Points Question What is the efficacy and safety of once-daily roflumilast cream, 0.15%, in patients with atopic dermatitis (AD)? Findings In 2 phase 3 randomized clinical trials of 1337 individuals with AD, significantly more patients treated with once-daily roflumilast cream, 0.15%, achieved Validated Investigator Global Assessment for Atopic Dermatitis success at 4 weeks than patients treated with vehicle cream. Roflumilast was well tolerated with low rates of adverse events in both trials.
Ruxolitinib cream improves sleep disturbances, itch in children with atopic dermatitis
Read more You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Ruxolitinib-treated patients achieved greater differences from baseline in itch intensity vs. vehicle. More ruxolitinib-treated patients reported a 6-point or higher improvement in sleep disturbance vs.
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, MD, MBA; Henrique D. Teixeira, PhD, MBA; Eric L. Simpson, MD, MCR; Antonio Costanzo, MD; Marjolein De Bruin-Weller, MD; Sebastien Barbarot, MD, PhD; Vimal H.
Phase 3 results show Vtama rapidly reduces itch in children, adults with atopic dermatitis
You've successfully added Dermatology: Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: As early as day 1, Vtama-treated patients saw an up to 1.6-point reduction in pruritus. By week 8, pruritus scores had decreased by 4.1 points in Vtama groups vs.
Interim results show roflumilast maintains, improves atopic dermatitis up to a year
You've successfully added Dermatology: Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: 46.1% and 51% of patients achieved vIGA-AD 0 or 1 plus a 2-point improvement from baseline at weeks 28 and 56. Roflumilast was well tolerated with no new safety signals were observed.
Errors in Figure 2 and Table 2 Footnotes
Errors in Figure 2 and Table 2 Footnotes Lebrikizumab With Corticosteroids for Moderate-to-Severe Atopic Dermatitis Eric L. Simpson, MD; Melinda Gooderham, MD; Andreas Wollenberg, MD; Stephan Weidinger, MD, PhD; April Armstrong, MD, MPH; Jennifer Soung, MD; Silvia Ferrucci, MD; Renata Gontijo Lima, MD; Michael M. Witte, PhD; Wen Xu, PhD; Hany ElMaraghy, MD; Chitra R.
Dupilumab improves hand, foot atopic dermatitis in phase 3 study
Source/Disclosures Source: Simpson E. Dupilumab treatment in patients with hand and foot atopic dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans.
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Atopic dermatitis is an inflammatory, itchy skin condition characterised by a fluctuating and chronic disease course. Effective therapies inhibit downstream immune signalling of interleukin (IL)-4, IL-13, IL-31,1 and Janus kinase activity.2 Biologics that target upstream cytokines, such as IL-1α, IL-33, and thymic stromal lymphopoietin (TSLP), have so far been unsuccessful.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
1. Silverberg JI Barbarot S Gadkari A et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021; 126: 417-428 2. Kay J Gawkrodger DJ Mortimer MJ Jaron AG The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994; 30: 35-39 3. Langan SM Abuabara K Henrickson SE Hoffstad O Margolis DJ Increased risk of cutaneous and systemic infections in atopic dermatitis—a cohort study. J Invest Dermatol.
‘Clinically meaningful’ results seen with tralokinumab
Source/Disclosures Source: Simpson E, et al. Clinically meaningful responses achieved with tralokinumab in adults with moderate to severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment. Presented at: Society for Investigative Dermatology (SID) Annual Meeting; May 18-21, 2022; Portland, Oregon.
Atopic dermatitis improvement seen with lebrikizumab plus topical steroids
April 11, 2022 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Key Points Question Is upadacitinib efficacy and safety maintained through 52 weeks of continuous treatment in patients with moderate to severe atopic dermatitis? Findings In this analysis of follow-up data from the large, global, replicate phase 3 Measure Up 1 and Measure Up 2 randomized clinical trials including a total of 1609 patients, once-daily upadacitinib (15 mg or 30 mg) provided durable efficacy with responses maintained through 52 weeks of treatment. No new safety risks were observed.
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary | Immunotherapy
ImmunotherapyVol. 14, No. 1 Plain Language Summary of PublicationOpen Access , , , , , , , , , , , , , , , , , & Abstract Atopic dermatitis (AD, also called atopic eczema) is a long-term skin disease that causes intensely itchy, red skin. Healthcare providers can prescribe medicated creams and ointments to reduce the signs and symptoms of AD. However, these treatments are not always enough to provide relief.
Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2 | SKIN The Journal of Cutaneous Medicine
Main Article Content Eric Simpson Oregon Medical Research Center, Portland, OR, USA Anderas Wollenberg Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany Weily Soong Alabama Allergy & Asthma Center and Clinical Research Center of Alabama, Birmingham, AL, United States Thomas Mark LEO Pharma A/S, Ballerup, Denmark Alexandra Kuznetsova LEO Pharma A/S, Ballerup, Denmark Louise Abildgaard Steffensen LEO Pharma A/S, Ballerup, Denmark...
Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement
Main Article Content Eric Simpson Oregon Health & Science University, Portland, OR, USA Robert Bissonnette Innovaderm Research, Montreal, QC, Canada Michael Kuligowski Incyte Corporation, Wilmington, DE, USA May Venturanza Incyte Corporation, Wilmington, DE, USA Kang Sun Incyte Corporation, Wilmington, DE, USA Jonathan Silverberg George Washington University School of Medicine Keywords ruxolitinib cream, atopic dermatitis, head and/or neck Abstract N/A References 1. Langan SM, et al. Lancet.
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
Key Points Question Are the efficacy and safety of oral upadacitinib superior to subcutaneous dupilumab in adults with moderate-to-severe atopic dermatitis (AD)? Findings This randomized, blinded, head-to-head comparator clinical trial of 692 patients with moderate-to-severe AD demonstrated clinically meaningful skin clearance and itch relief, with statistically significant superiority for upadacitinib compared with dupilumab.
Pioneering Best Practices in Atopic Dermatitis: Results from the Quality of Care Initiative
Purpose and Mission of the Atopic Dermatitis Quality of Care Initiative Professor Emma Guttman For many years, AD has been deprioritised in favour of services deemed more medically urgent. New systemic therapies that are able to effectively treat both the disease and its comorbidities have also become available. More recently, patient advocates have taken important steps to increase awareness of AD.
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, skin pain, and sleep disturbances. Currently, dupilumab is the only systemic therapy and biologic medication approved by the United States Food and Drug Administration for moderate-to-severe AD in adults and children. There is a sparsity of literature available on determining treatment failure with dupilumab and the next steps health care providers can take to treat AD.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Summary Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and safety of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis.
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis
Key Points Question What is the long-term (68-week) efficacy of baricitinib, 4 and 2 mg, in patients with moderate to severe atopic dermatitis who were treatment responders or partial responders?
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Related Articles Abstract Background The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Background Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. Objective To evaluate the efficacy and safety of baricitinib monotherapy in a North American phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Methods Patients (N = 440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg).
New NEA Survey Puts Dollar Amounts on Cost of Living with AD
Fully 42 percent of Americans living with atopic dermatitis (AD) spend $1,000 or more out of pocket (OOP) every year to manage their eczema, accrdong to a new survey from the National Eczema Association (NEA). While the median annual estimated OOP expense is $600 across all survey respondents, annual OOP costs equal to or exceeding $5,000 were reported by 8.5% of participants, the survey found. The findings are published (in part) in Dermatitis.
Arcutis Moves Another Candidate Into Phase 3 Trials
Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. is now doing the same for topical roflumilast foam (ARQ-154) for seborrheic dermatitis following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
LEO Pharma Data: Tralokinumab Benefits Adult AD
January 19, 2021 Results from a post-hoc subanalysis of the Phase 3 ECZTRA 3 trial demonstrate the potential for LEO Pharma’s tralokinumab as a treatment for adults with moderate-to-severe atopic dermatitis. Investigational tralokinumab has not yet been approved by any regulatory authority. The data, shared virtually at the 2021 Winter Clinical Dermatology Conference, demonstrates safety and efficacy of tralokinumab in 100 US adult patients with moderate-to-severe atopic dermatitis.
Study: Acute Itching in AD Linked to Environmental Triggers
Allergens in the environment often are to blame for episodes of acute itch in eczema patients, and that this itching often doesn’t respond to antihistamines because the itch signals are being carried to the brain along a previously unrecognized pathway that current drugs don’t target, according to researchers from Washington University School of Medicine in St. Louis.
Abrocitinib for atopic dermatitis - Authors' reply
Shelley Uppal and colleagues suggested that it cannot be concluded from our paper 1 Simpson EL Sinclair R Forman S et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet.
Novartis: Ligelizumab Receives Breakthrough Therapy Designation in CSU
Ligelizumab from Novartis now has Breakthrough Therapy designation from FDA for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. Ligelizumab (QGE031) is currently being compared with omalizumab (Xolair® ) in an ongoing Phase 3 clinical trial programs (including PEARL 1 and PEARL 2) that have recruited more than 2,000 patients globally across 48 countries.
Cerave Poll: Healthier Skin Tops New Year’s Resolutions
The COVID-19 pandemic has taken its toll on every aspect of life including skin, according to a new survey from CeraVe. Fully 62 percent of Americans agree that they have experienced more skin troubles during the pandemic than ever before, with top concerns being dryness (51%) and itchiness (31%), two symptoms that can also be a result of disrupted ceramide levels in skin. Unfortunately, winter also heightens these issues.
Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials | SKIN The Journal of Cutaneous
Main Article Content Eric Simpson Department of Dermatology, Oregon Health & Science University, Portland, OR, USA Joseph Merola Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Jonathan Silverberg Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA Rebecca Zachariae LEO Pharma A/S, Ballerup, Denmark Rebecca Olsen LEO Pharma A/S, Ballerup, Denmark Andreas Wollenberg Klinikum der Universität München,...
Six Investigators to Receive NEA Grants for Eczema Research
December 22, 2020 The new research will explore all key aspects of eczema from genetic components, to the science behind itch and inflammation, to new pathways for potential therapies. Research Updates The National Eczema Association (NEA) announced the recipients for its 2020 research grants. Six investigators will receive grants for eczema research, representing grants totaling $310,000.
Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials | SKIN The Journal of Cutaneous Medicine
Main Article Content Eric Simpson Department of Dermatology, Oregon Health & Science University, Portland, OR, USA Thomas Werfel Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany Thomas Bieber Department of Dermatology and Allergy, University Medical Center, Bonn, Germany Louise Steffensen LEO Pharma A/S, Ballerup, Denmark Alexandra Kuznetsova LEO Pharma A/S, Ballerup, Denmark Marie Østerdal LEO Pharma A/S, Ballerup, Denmark Hidehisa Saeki Department of...
Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: A case report
Key words atopic dermatitis breastfeeding dupilumab pregnancy severe Abbreviations used: AD (atopic dermatitis), IL (interleukin), Th1 (T-helper), TNF (tumor necrosis factor) Introduction Atopic dermatitis (AD) is an inflammatory skin condition affecting 3% to 10% of adults and 10% to 20% of children globally. Systemic therapies such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil have variable levels of efficacy and potential adverse effects. 3 Ponticelli C. Moroni G.
Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials
To the Editor: Moderate to severe atopic dermatitis (AD) negatively affects daily functioning, quality of life (QoL), and work productivity, 1 Eckert L. Gupta S. Amand C. Gadkari A. Mahajan P. Gelfand J.M. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017; 77: 274-279 more so for patients with inadequate symptom control.
Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis
Background Current valid instruments that measure the signs of atopic dermatitis in clinical trials may not be suitable for clinical practice because of their complexity. The product of a clinician-derived 5-point signs global assessment and body surface area (SGA × BSA) may represent a simple approach to quickly assess the severity of signs in patients with atopic dermatitis in clinical practice. Objectives Evaluate the basic measurement properties of the SGA × BSA.
Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)
Main Article Content Eric L Simpson Hiroyuki Fujita Kazuhiko Arima Jennifer Hamilton Yufang Lu Ana B Rossi Ashish Bansal Keywords Atopic Dermatitis, Biologics, Dupilumab, Biomarker Abstract Abstract not available. Abstract 0 | Poster PDF Downloads 0 References 1. Eichenfield LF, et al. J Am Acad Dermatol. 2014;70:338-51. 2. Kakinuma T, et al. J Allergy Clin Immunol. 2001; 107:535-41. 3. Jahnz-Rozyk K, et al. Allergy. 2005; 60:685-8. 4. Thijs JL, et al.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Background An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization. Objectives To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability. Methods Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM).
New and Emerging Biologics for Atopic Dermatitis
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel In This Article Abstract and Introduction Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by complex pathophysiology involving both skin barrier dysfunction and aberrant type 2 inflammation/immune responses.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Summary Background Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis.
Tralokinumab effective in dermatitis treatment
June 14, 2020 1 min read Source/Disclosures Source: Simpson E. Efficacy and safety of tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: Results from two 52-week Phase 3 trials (ECZTRA 1 and ECZTRA 2). Presented at AAAD VMX; June 12-14, 2020; Virtual meeting. Disclosures: Simpson is an investigator and consultant for LEO Pharma.
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS
Background Pruritus (itch) is a cardinal symptom in atopic dermatitis (AD). Objective To evaluate the timing and effect of dupilumab on itch. Methods Analysis of data from 1505 patients with moderate to severe AD included in 4 randomized controlled studies, treated for up to 52 weeks.
Acitretin therapy for Galli-Galli disease
Key words Galli-Galli disease POGLUT1 reticulate pigmentation Abbreviations used: DDD (Dowling-Degos disease), GGD (Galli-Galli disease) Introduction Galli-Galli disease (GGD) is a rare autosomal dominant genodermatosis, characterized by hyperkeratotic papules and progressive reticular hyperpigmentation involving the neck, trunk, and proximal extremities. GGD falls on a spectrum of reticulate hyperpigmentation disorders, and is thought to be an acantholytic variant of Dowling-Degos disease (DDD).
Prevalence of Allergic Disease in Foreign-Born American Children
Abstract Importance Improved understanding of allergic disease epidemiology lead to novel therapeutic and prevention strategies. Objectives To study the association between US birthplace and prevalence of childhood allergic disease and to determine the effects of prolonged US residence on allergic disease. Design, Setting, Participants Cross-sectional questionnaire distributed to 91 642 children aged 0 to 17 years enrolled in the 2007-2008 National Survey of Children's Health.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Eric
Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack